The estimated Net Worth of John F Thero is at least $28.4 Million dollars as of 30 July 2021. Mr. Thero owns over 26,944 units of Amarin Corp stock worth over $1,925,380 and over the last 9 years he sold AMRN stock worth over $17,555,731. In addition, he makes $8,929,540 as President, Chief Executive Officer und Director at Amarin Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Thero AMRN stock SEC Form 4 insiders trading
John has made over 27 trades of the Amarin Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 26,944 units of AMRN stock worth $15,897 on 30 July 2021.
The largest trade he's ever made was exercising 750,000 units of Amarin Corp stock on 9 November 2020 worth over $2,550,000. On average, John trades about 98,702 units every 22 days since 2015. As of 30 July 2021 he still owns at least 3,263,356 units of Amarin Corp stock.
You can see the complete history of Mr. Thero stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Thero biography
John F. Thero CPA serves as President, Chief Executive Officer, Director of the Company. He was promoted to President and Chief Executive Officer, and appointed to the Board, effective January 2014. Prior to his promotion, he was Amarin’s President since November 2010 before which he was Amarin’s Chief Financial Officer. Mr. Thero has more than 25 years of senior financial and operational management experience, including supporting the growth of life science companies for over 15 years. Prior to Amarin, Mr. Thero also served in a variety of roles and has helped manage both the successful commercial growth and the successful sale of companies between 1994 and 2007. Mr. Thero began his professional career at Arthur Andersen LLP, during which time he became a Certified Public Accountant. He currently serves as a member of the board of directors of Chiasma, Inc. He received a B.A. in Economics from the College of the Holy Cross. In 2019, Mr. Thero was named Ernst & Young LLP Entrepreneur of the Year for Life Sciences. The Board believes that Mr. Thero’s experience in management positions at life sciences companies, as well as his experience as Amarin’s President and Chief Executive Officer and, before that, as Amarin’s President and Chief Financial Officer, provide him with the appropriate qualifications and skills to serve as a member of the Board.
What is the salary of John Thero?
As the President, Chief Executive Officer und Director of Amarin Corp, the total compensation of John Thero at Amarin Corp is $8,929,540. There are no executives at Amarin Corp getting paid more.
How old is John Thero?
John Thero is 59, he's been the President, Chief Executive Officer und Director of Amarin Corp since 2014. There are 5 older and 12 younger executives at Amarin Corp. The oldest executive at Amarin Corp is Patrick O'Sullivan, 78, who is the Non-Executive Independent Director.
What's John Thero's mailing address?
John's mailing address filed with the SEC is C/O CHIASMA, INC., 140 KENDRICK STREET, BUILDING C EAST, NEEDHAM, MA, 02494.
Insiders trading at Amarin Corp
Over the last 13 years, insiders at Amarin Corp have traded over $25,876,836 worth of Amarin Corp stock and bought 581,426 units worth $751,974 . The most active insiders traders include John F Thero, Steven B Ketchum und David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of $29,442. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth $102,400.
What does Amarin Corp do?
amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.
What does Amarin Corp's logo look like?
Complete history of Mr. Thero stock trades at Amarin Corp und Chiasma Inc
Amarin Corp executives and stock owners
Amarin Corp executives and other stock owners filed with the SEC include:
-
John Thero,
President, Chief Executive Officer, Director -
Stephen Ketchum,
President - Research and Development, Senior Vice President, Chief Scientific Officer -
Joseph Kennedy,
Executive Vice President, General Counsel, Secretary, Strategic Initiatives -
Aaron Berg,
Senior Vice President, Chief Commercial Officer -
Michael Kalb,
Chief Financial Officer, Senior Vice President, Assistant Secretary -
Joseph Zakrzewski,
Non-Executive Independent Director -
Dr. Steven B. Ketchum Ph.D.,
Pres of R&D, Exec. VP and Chief Scientific Officer -
Dr. Steven B. Ketchum,
Pres of R&D, Sr. VP and Chief Scientific Officer -
Michael W. Kalb,
CFO, Sr. VP & Assistant Sec. -
Aaron D. Berg,
Exec. VP & Pres of U.S. -
Elisabeth Schwartz,
IR Contact Officer -
Jan van Heek,
Non-Executive Independent Director -
David Stack,
Non-Executive Independent Director -
Kristine Peterson,
Non-Executive Independent Director -
Patrick O'Sullivan,
Non-Executive Independent Director -
Lars Ekman,
Non-Executive Independent Chairman of the Board -
Alan J. Wills B.A., BA (Zoology), M.B.A., MBA,
Exec. VP of Corp. Bus. Devel. -
Jason M. Marks J.D.,
Chief Legal Officer & Corp. Sec. -
Karim Mikhail,
Pres, CEO & Director -
Donna Pasek,
Sr. VP of HR -
Rami Daoud,
Sr. VP of Corp. Devel. -
Alina Kolomeyer,
Director of Communications -
Daniel S. Dunham,
Sr. VP & Chief Pharmaceutical Compliance Officer -
Healthcare Partners Ltd. Fo...,
Director -
Louis Iii Sterling,
-
Oliver O'connor,
-
Paul Cohen,
-
Kostas D Odysseas,
-
Mark Di Paolo,
-
Steven B Ketchum,
Chief Scientific Officer -
Murray Stewart,
-
Karim Mikhail,
President and CEO -
Jason M. Marks,
EVP,Chief Global Legal Officer -
Alfonso G Zulueta,
-
Erin S. Enright,
-
Thomas Charles Reilly,
EVP and CFO -
Geraldine Murphy,
-
Adam Mark Berger,
-
Diane E. Sullivan,
-
Olsen Per Wold,
Director -
Keith Horn,
-
Jonathan Provoost,
EVP, Chief Legal Officer -
Patrice Eadon Bonfiglio,
-
Patrick Holt,
President and CEO